Abstract
While valuable as independent tools, imaging scanners can be coupled together in research applications to provide a richer understanding of the anatomical, functional, and molecular mechanisms driving disease and drug efficacy. The work associated with these experiments must add value to the project without crippling experiment throughput. Dr. Silva will explore the value of compact MRI integrated into multi-modal laboratory with emphasis on bioluminescence and nuclear medicine examples.
Cancer, Multi-Modality, Drug Development, LumiQuant, Bioluminescence
Cancer, Multi-Modality, Drug Development
ICON, VivoQuant, LumiQuant
Matt Silva, Ph.D.
Director, Imaging Research, InviCRO
Former Imaging Director of Research, Amgen (Thousand Oaks, CA) and Head of Imaging Sciences, Millennium Pharmaceuticals (Boston, MA)
